Clinical Efficacy of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Melasma
Main Article Content
Keywords
Thiamidol, Melasma
Abstract
Clinical Efficacy of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Melasma
Dennis Roggenkamp1, Adel Sammain1, Manuela Fürstenau2, Martina Kausch2, Thierry Passeron3,4, Ludger Kolbe2
1International Medical Management, Beiersdorf AG, Hamburg, Germany, 2Research & Development, Beiersdorf AG, Hamburg, Germany, 3Centre Méditerranéen de Médecine Moléculaire – C3M, University Côte d’Azur, INSERM U1065, Nice, France, 4Department of Dermatology, University Côte d’Azur, CHU Nice, Nice, France
Thiamidol (isobutylamido thiazolyl resorcinol) was the most potent inhibitor of human tyrosinase identified out of 50,000 screened substances. In vivo, it was well tolerated and improved melasma significantly. This was the first 24-week, randomized, double-blind, vehicle-controlled, cosmetic clinical study to assess the efficacy and tolerability of Thiamidol in moderate-to-severe melasma in phototype III-V subjects with subsequent regression phase. Females allocated to the Thiamidol treatment group (n=23), applied daily Thiamidol-based Serum followed either by a Thiamidol cream with SPF 30 in the morning or by Thiamidol cream without SPF in the evening. The vehicle group (25 females) followed the same skin care routine using the corresponding vehicle formulations. Subjects returned for a follow-up visit 13-20 weeks after treatment (regression phase). Assessments included clinical photography, Melasma Area and Severity Index (MASI), skin lightness, quality of life, and tolerability. Baseline demographics and hyperpigmentation were well balanced across all treatment groups. Clinical photography and MASI improved significantly with Thiamidol versus baseline (p < 0.001) and vehicle (p < 0.001- 0.043) at all time points up to treatment end. At follow-up, MASI was still significantly lower than at baseline but similar for treatment and vehicle groups. Skin lightness and quality of life improved significantly versus baseline without significant differences between treatment and vehicle groups. This study demonstrated that Thiamidol is well tolerated and superior in improving melasma compared to baseline and vehicle over a treatment period of 24 weeks.
References
2. Hexsel D, Lacerda DA, Cavalcante AS, et al. Int J Dermatol. 2014;53:440-444.
3. Achar A, Rathi SK. Indian J Dermatol. 2011;56:380-382.
4. Amatya B, Jha AK, Shrestha S. BMC Dermatol. 2020;20:4.
5. Maymone MBC, Neamah HH, Wirya SA, et al. J Am Acad Dermatol. 2017;77:775-778.
6. Gillbro JM, Olsson MJ. Int J Cosmet Sci. 2011;33:210-221.
7. Grimes PE, Ijaz S, Nashawati R, et al. Int J Womens Dermatol. 2019;5:30-36.
8. Mann T, Gerwat W, Batzer J, et al. J Invest Dermatol. 2018;138:1601-1608.
9. Mann T, Scherner C, Rohm KH, et al. Int J Mol Sci. 2018;19:690.
10. Arrowitz C, Schoelermann AM, Mann T, et al. J Invest Dermatol. 2018;139:1691-1698.
11. Philipp-Dormston WG, Vila Echague A, Perez Damonte SH, et al. Int J Cosmet Sci. 2020;42:377-387.
12. Roggenkamp D, Dlova NC, Mann T, et al. Int J Cosmet Sci. 2021;43:292-301.
13. Pandya AG, Hynan LS, Bhore R, et al. J Am Acad Dermatol. 2011;64:78-83.e2.
14. Clarys P, Alewaeters K, Lambrecht R, et al. Skin Res Technol. 2000;6:230-238.
15. Taylor S, Westerhof W, Im S, et al. J Am Acad Dermatol. 2006;54(5 Suppl 2):S282-S290.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.